FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103269419> ?p ?o ?g. }

• W2103269419 endingPage "596.e1" @default.
• W2103269419 startingPage "591" @default.
• W2103269419 abstract "To compare the visual outcomes of intravitreal bevacizumab (Avastin; Genentech Inc, South San Franciso, California, USA) and sub-Tenon triamcinolone acetonide (TA) for choroidal neovascularization attributable to pathologic myopia (mCNV).Retrospective, comparative, interventional case series.Fifty-four consecutive eyes of 53 patients with mCNV treated with either sub-Tenon TA or intravitreal bevacizumab in an institutional setting were included. Twenty eyes were treated with sub-Tenon TA and 34 eyes were treated with intravitreal bevacizumab. The main outcome measures included best-corrected visual acuity (BCVA) 12 months after the initial injection and logarithm of the minimum angle of resolution gain from baseline compared with analysis of covariance (ANCOVA).At 12 months, the BCVA improved by 1.9 lines in the intravitreal bevacizumab group and worsened by 0.3 lines in the sub-Tenon TA group. Thus, the intravitreal bevacizumab group had significantly greater visual improvement than the sub-Tenon TA group (P < .01). Statistical analysis (ANCOVA) revealed that age (P = .01), pretreatment BCVA (P < .01), and the treatment choice (intravitreal bevacizumab or sub-Tenon TA; P < .01) correlated significantly with the BCVA and the BCVA gain at 12 months. The refractive error was of borderline significance (P = .06).Although this study is limited because of its retrospective nature, intravitreal bevacizumab seems to result in a more favorable visual outcome than sub-Tenon TA in the treatment of mCNV. Patient age, the BCVA before treatment, and the refractive error must be considered to initiate the treatment." @default.
• W2103269419 created "2016-06-24" @default.
• W2103269419 creator A5041468000 @default.
• W2103269419 creator A5061755175 @default.
• W2103269419 creator A5071301207 @default.
• W2103269419 creator A5080608168 @default.
• W2103269419 creator A5087418402 @default.
• W2103269419 date "2009-10-01" @default.
• W2103269419 modified "2023-09-27" @default.
• W2103269419 title "Intravitreal Bevacizumab vs Sub-Tenon Triamcinolone Acetonide for Choroidal Neovascularization Attributable to Pathologic Myopia" @default.
• W2103269419 cites W110906275 @default.
• W2103269419 cites W115342157 @default.
• W2103269419 cites W1575701919 @default.
• W2103269419 cites W1975208123 @default.
• W2103269419 cites W1979589798 @default.
• W2103269419 cites W1996418653 @default.
• W2103269419 cites W1999809746 @default.
• W2103269419 cites W2003520592 @default.
• W2103269419 cites W2007761826 @default.
• W2103269419 cites W2009175584 @default.
• W2103269419 cites W2012519330 @default.
• W2103269419 cites W2016068843 @default.
• W2103269419 cites W2029261957 @default.
• W2103269419 cites W2032587733 @default.
• W2103269419 cites W2039446733 @default.
• W2103269419 cites W2045901850 @default.
• W2103269419 cites W2051258987 @default.
• W2103269419 cites W2053386201 @default.
• W2103269419 cites W2058815839 @default.
• W2103269419 cites W2069220590 @default.
• W2103269419 cites W2074594555 @default.
• W2103269419 cites W2078566494 @default.
• W2103269419 cites W2088702185 @default.
• W2103269419 cites W2091038445 @default.
• W2103269419 cites W2092226078 @default.
• W2103269419 cites W2128808952 @default.
• W2103269419 cites W2134586613 @default.
• W2103269419 cites W2155905635 @default.
• W2103269419 cites W2164200654 @default.
• W2103269419 cites W233579014 @default.
• W2103269419 cites W2897510582 @default.
• W2103269419 cites W2728697159 @default.
• W2103269419 doi "https://doi.org/10.1016/j.ajo.2009.05.026" @default.
• W2103269419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19589497" @default.
• W2103269419 hasPublicationYear "2009" @default.
• W2103269419 type Work @default.
• W2103269419 sameAs 2103269419 @default.
• W2103269419 citedByCount "13" @default.
• W2103269419 countsByYear W21032694192012 @default.
• W2103269419 countsByYear W21032694192013 @default.
• W2103269419 countsByYear W21032694192015 @default.
• W2103269419 countsByYear W21032694192017 @default.
• W2103269419 countsByYear W21032694192021 @default.
• W2103269419 countsByYear W21032694192023 @default.
• W2103269419 crossrefType "journal-article" @default.
• W2103269419 hasAuthorship W2103269419A5041468000 @default.
• W2103269419 hasAuthorship W2103269419A5061755175 @default.
• W2103269419 hasAuthorship W2103269419A5071301207 @default.
• W2103269419 hasAuthorship W2103269419A5080608168 @default.
• W2103269419 hasAuthorship W2103269419A5087418402 @default.
• W2103269419 hasConcept C118487528 @default.
• W2103269419 hasConcept C119767625 @default.
• W2103269419 hasConcept C127413603 @default.
• W2103269419 hasConcept C141071460 @default.
• W2103269419 hasConcept C154049752 @default.
• W2103269419 hasConcept C2776694085 @default.
• W2103269419 hasConcept C2777802072 @default.
• W2103269419 hasConcept C2778257484 @default.
• W2103269419 hasConcept C2778903070 @default.
• W2103269419 hasConcept C2781359195 @default.
• W2103269419 hasConcept C66938386 @default.
• W2103269419 hasConcept C71924100 @default.
• W2103269419 hasConceptScore W2103269419C118487528 @default.
• W2103269419 hasConceptScore W2103269419C119767625 @default.
• W2103269419 hasConceptScore W2103269419C127413603 @default.
• W2103269419 hasConceptScore W2103269419C141071460 @default.
• W2103269419 hasConceptScore W2103269419C154049752 @default.
• W2103269419 hasConceptScore W2103269419C2776694085 @default.
• W2103269419 hasConceptScore W2103269419C2777802072 @default.
• W2103269419 hasConceptScore W2103269419C2778257484 @default.
• W2103269419 hasConceptScore W2103269419C2778903070 @default.
• W2103269419 hasConceptScore W2103269419C2781359195 @default.
• W2103269419 hasConceptScore W2103269419C66938386 @default.
• W2103269419 hasConceptScore W2103269419C71924100 @default.
• W2103269419 hasIssue "4" @default.
• W2103269419 hasLocation W21032694191 @default.
• W2103269419 hasLocation W21032694192 @default.
• W2103269419 hasOpenAccess W2103269419 @default.
• W2103269419 hasPrimaryLocation W21032694191 @default.
• W2103269419 hasRelatedWork W1502656374 @default.
• W2103269419 hasRelatedWork W1979874741 @default.
• W2103269419 hasRelatedWork W1991963023 @default.
• W2103269419 hasRelatedWork W1993747607 @default.
• W2103269419 hasRelatedWork W2000192077 @default.
• W2103269419 hasRelatedWork W2049428073 @default.
• W2103269419 hasRelatedWork W2065629733 @default.
• W2103269419 hasRelatedWork W2412914714 @default.
• W2103269419 hasRelatedWork W3030890346 @default.

• next